{"id":689627,"date":"2022-09-28T07:33:11","date_gmt":"2022-09-28T11:33:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/"},"modified":"2022-09-28T07:33:11","modified_gmt":"2022-09-28T11:33:11","slug":"cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/","title":{"rendered":"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Program to Provide $100,000 in Support of Communications and Outreach for Patient<br \/> Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>Deadline for Applications is November 11<\/em><br \/>\n        <sup><br \/>\n          <em>th<\/em><br \/>\n        <\/sup><br \/>\n        <em>, 2022<\/em>\n      <\/p>\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Sept.  28, 2022  (GLOBE NEWSWIRE) &#8212;  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure or hypertrophic cardiomyopathy (HCM) communities, and is intended to support increased capacity in communications and outreach.<\/p>\n<p align=\"justify\">\u201cWe initiated this program in 2018 with the goal of helping patient advocacy organizations advance often under-funded marketing and communications efforts,\u201d said Mary Pomerantz, Cytokinetics\u2019 Director of Advocacy. \u201cOver the past five years, our grantees have reached new audiences, built awareness programs and amplified their organizations. We look forward to seeing the continued impact of this program.\u201d<\/p>\n<p align=\"justify\">The Cytokinetics Communications Grant Program supports patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communication or outreach initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Grant program supports programming or personnel, depending on each organization\u2019s needs. The recipients of the 2022 Cytokinetics Communications Grants were Mended Hearts, the Hypertrophic Cardiomyopathy Association, I AM ALS, the Les Turner ALS Foundation and The ALS Association Northern Ohio Chapter.<\/p>\n<p align=\"justify\">Eligible organizations must have nonprofit organization status in the United States and serve the cardiovascular or neuromuscular patient communities in ALS, heart failure or HCM. The deadline to apply is November 11, 2022 and the grant recipients will be announced in January 2023.<\/p>\n<p align=\"justify\">Organizations applying for the grant are required to submit a proposal outlining what activities the Cytokinetics Communications Grant Program will support and the potential impact of the funding. Recipients are responsible for providing an outcomes report to Cytokinetics to measure impact at the end of the funding period. For more information on application criteria, and instructions for how to apply, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0NrjVaH0ui35MpJh9EA5BHTqtM0qbbKivh3pXm67ye9XKJ1AUMzSxqfPyblD0YGHWequZ7c2SKJejrqPTYLgu_j7CH6wDIApGw_8Wn0MIPU1Swkcthj1yw-cTP3EEfW7vUayZuhzDCrz85ym50Kdkw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/cytokinetics.com\/communicationsgrant\/<\/a>. <\/p>\n<p><strong>About Cytokinetics<\/strong><\/p>\n<p align=\"justify\">Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of <em>omecamtiv mecarbil<\/em>, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing <em>aficamten<\/em>, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of <em>aficamten<\/em> in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). <em>Aficamten<\/em> is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing <em>reldesemtiv<\/em>, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.<\/p>\n<p align=\"justify\">For additional information about Cytokinetics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8PnXuzjOmx4HyWMEGDWV2BPCiaBIEYFD8bRH6--3-b3uK5-fEvkXvy7MgtLOrutmnu4nqeAB3x3ggm39SKW3ch1xzPOWLDuhZU-CMdKZGoM=\" rel=\"nofollow noopener\" target=\"_blank\">www.cytokinetics.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TMwkIS8cP9jwx9frkyN7GxR3a4lqOI0SGlnqRdrVwQtttSs4BXaO9dtzrE_QYI_BREa0u_srSU7t-OAjEagBpQ==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RL-2yg4TDr2WrpFTFrMUrftET9KsIHjjvY0Dz7TyiqaMdHl6GOxtX10PsK1APuvbpVmW_AH5gN0UDFpX2suDF0MhEATeK2JEizKizEv7fpY=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zQrcV_NWgckrbh0wchd0DRlkf1RkvgNEJ50R7efNvKtn8Cl7EbtW6DlOl-7pYBuTskFjjAXDyrXxf7j7NtiSpvDVXbzDtO2zFh0IWoUtPi0=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nSvgiT2ELEcYe2Zr8_hMPwtAIMdLSmIvfaJ47FuJ_0A8hDq_K6-Y5zeiLaIkun7xl9F418GOSgHlQvn7WihmYfkSxde3DOQvhMZIVLsSu81uY2VAHqIZvDF8mJ53VOWp\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d).\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\u2019s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics\u2019 and its partners\u2019 research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics\u2019 business outlines in Cytokinetics\u2019 filings with the\u00a0Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics\u2019 actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that\u00a0Cytokinetics\u00a0makes in this press release speak only as of the date of this press release.\u00a0Cytokinetics\u00a0assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Diane Weiser<br \/>Senior Vice President, Corporate Communications, Investor Relations<br \/>(415) 290-7757<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzdmOTU2M2ItOTUyMS00YWFiLWEyYjktZWU0ZDI1NjhkZDc1LTEwMTY2NzY=\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11 th , 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure or hypertrophic cardiomyopathy (HCM) communities, and is intended to support increased capacity in communications and outreach. \u201cWe initiated this program in 2018 with the goal of helping patient advocacy organizations advance often under-funded marketing and communications efforts,\u201d said Mary Pomerantz, Cytokinetics\u2019 Director of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689627","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11 th , 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure or hypertrophic cardiomyopathy (HCM) communities, and is intended to support increased capacity in communications and outreach. \u201cWe initiated this program in 2018 with the goal of helping patient advocacy organizations advance often under-funded marketing and communications efforts,\u201d said Mary Pomerantz, Cytokinetics\u2019 Director of &hellip; Continue reading &quot;Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T11:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program\",\"datePublished\":\"2022-09-28T11:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/\"},\"wordCount\":756,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/\",\"name\":\"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=\",\"datePublished\":\"2022-09-28T11:33:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program - Market Newsdesk","og_description":"Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11 th , 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure or hypertrophic cardiomyopathy (HCM) communities, and is intended to support increased capacity in communications and outreach. \u201cWe initiated this program in 2018 with the goal of helping patient advocacy organizations advance often under-funded marketing and communications efforts,\u201d said Mary Pomerantz, Cytokinetics\u2019 Director of &hellip; Continue reading \"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-28T11:33:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program","datePublished":"2022-09-28T11:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/"},"wordCount":756,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/","name":"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=","datePublished":"2022-09-28T11:33:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDY4OSM1MTc1NjA3IzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-call-for-proposals-for-its-fifth-annual-communications-grant-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689627"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689627\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}